OC-0317: Validation of a hypoxia TCP model and dose painting in HNC: Planned interim analysis of a phase II trial

Thorwarth, Daniela; Mönnich, David; Wack, Linda-Jacqueline; Pfannenberg, C.; Alber, M.; Zips, Daniel; Welz, Stephan

doi:10.1016/s0167-8140(15)30422-9

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The planned interim analysis for the first 20 patients recruited into this study showed that dose escalation in this order of magnitude is well tolerated. Additionally, results of this study have thus far confirmed a prognostic model relating the dynamic FMISO-PET data to the individual tumour control probability established in an earlier study (Thorwarth et al 2014).…”

Section: Clinical Studiessupporting

confidence: 85%

FMISO as a Biomarker for Clinical Radiation Oncology

Zschaeck

Steinbach

Troost

2016

Molecular Radio-Oncology

View full text Add to dashboard Cite

Tumour hypoxia is a well-known negative prognostic marker in almost all solid tumours. [18F]Fluoromisonidazole (FMISO)-positron emission tomography (PET) is a non-invasive method to detect tumour hypoxia. Compared to other methods of hypoxia assessment it possesses some considerable advantages: It is non-invasive, it delivers spatial information on the hypoxia distribution within the entire tumour volume, and it can be repeated during the course of radio(chemo)therapy. This chapter briefly describes different methods of hypoxia evaluation and focuses on hypoxia PET imaging, with the most commonly used tracer being FMISO. The preclinical rationale and clinical studies to use FMISO-PET for patient stratification in radiation therapy are discussed as well as possible agents or radiation-dose modifications to overcome hypoxia.

show abstract

Section: Clinical Studiessupporting

confidence: 85%

FMISO as a Biomarker for Clinical Radiation Oncology

Zschaeck

Steinbach

Troost

2016

Molecular Radio-Oncology

View full text Add to dashboard Cite

show abstract

“…The planned interim analysis for the first 20 patients recruited into this study showed that dose escalation on this order of magnitude is well tolerated (41). Furthermore, results from this study have confirmed a prognostic model relating individual tumor control probability to the dynamic 18 F-fluoromisonidazole PET data established in an earlier study (44).…”

Section: Pet For Radiation Treatment Adaptation and Normal-tissue Chasupporting

confidence: 71%

Imaging-Based Treatment Adaptation in Radiation Oncology

2015

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to (1) understand the clinical implications of tumor characterization using different PET tracers before and during radiotherapy or chemoradiotherapy; (2) discuss the role of other functional imaging modalities (CT and MRI) in current oncology practice; and (3) introduce additional applications of PET imaging, such as in high-energy proton-beam therapy.

show abstract